Targeted Fc2′-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice
Authors: Fishman, A.1; Prus, D.2; Belostotsky, R.1; Lorberboum-Galski, H.1
Source: Clinical & Experimental Immunology, Volume 119, Number 3, March 2000 , pp. 398-403(6)
Publisher: Blackwell Publishing
Abstract:
The alarming increase in the incidence of allergic diseases in the past decade has led to a clear call for more effective treatment. Recently, we reported on the construction of a chimeric protein for targeted elimination of cells expressing FcεRI receptors. This chimeric protein, designated Fc2′-3-PE40, is composed of a Fc fragment of mouse IgE attached to a truncated form of Pseudomonas exotoxin. The Fc2′-3-PE40 chimeric protein was found to be highly cytotoxic to mouse mast cell lines and primary mouse mast cells. We now demonstrate that Fc2′-3-PE40 successfully prevents the development of passive cutaneous anaphylaxis reaction (PCA) in mice. Treatment with Fc2′-3-PE40 for 7 days prevented the PCA reaction in mice by 80% compared with that in control mice given only PBS. Fc2′-3-PE40M, the mutated, enzymatically inactive analogue of Fc2′-3-PE40, did not display this activity. Fc2′-3-PE40 was also effective when given as a single dose 16 h before antigen exposure, resulting in complete inhibition of the PCA reaction. Moreover, treatment with Fc2′-3-PE40 did not cause mast cell degranulation, as the serum histamine values of mice treated with Fc2′-3-PE40 were within the range obtained for control, untreated mice. Thus, the Fc2′-3-PE40 chimeric protein offers a novel approach to the treatment of allergic disorders.Keywords: mast cells; basophils; allergy; cytotoxicity; Fc receptors; in vivo animal models
Document Type: Research article
DOI: 10.1046/j.1365-2249.2000.01151.x
Affiliations: 1: Department of Cellular Biochemistry, Hebrew University-Hadassah Medical School, and 2: Department of Pathology, Hadassah University Hospital, Jerusalem, Israel

Click here for Page Help